Atrium Innovations acquires Enzimas

Atrium Innovations Inc. (TSX: ATB), a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today announced the acquisition of Enzimas S.A., a manufacturer of Trypsin and Chymotrypsin enzymes based in Lujan, Argentina.

Through this transaction, the Company acquires a manufacturing facility and process that is approved by various regulatory bodies in countries where Wobenzym products are sold. This acquisition was aimed at securing two critical enzymes, which are in relatively short supply worldwide in the quality required for the formulation of Wobenzym products. Furthermore, the transaction is supported by an attractive potential return on investment based on anticipated manufacturing cost savings.